Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01851083|
Recruitment Status : Active, not recruiting
First Posted : May 10, 2013
Last Update Posted : September 12, 2019
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury||Biological: autologous bone marrow mononuclear cells Other: Placebo Infusion||Phase 1 Phase 2|
Study Design: Multicenter, randomized, blinded, placebo controlled, Bayesian adaptive dose escalation design.
Study Intervention: Single dose administered within 48 hours from time of injury. Controls will undergo a sham harvest and receive similarly labeled/external appearance and volume of 0.9% NaCl. BMMNC's will be harvested and undergo processing under cGMP conditions to obtain 6x10^6 cells/kg or 10x10^6 cells/kg weight. The cellular product/placebo will be infused within 48 hours of injury.
Safety Monitoring & Follow-Up: Subjects will be monitored for infusion related toxicity post-infusion through hospital discharge and follow-up return study visits. Laboratory and imaging studies will be repeated at the 1, 6, and 12-month follow-up visits. A medical safety monitor (MSM) will review blinded SAE reports following post-infusion Day 14 for each subject in real time to ensure good clinical practice and to quickly identify safety concerns. The MSM will remain blinded to the treatment assignment, unless the NINDS appointed DSMB approves unblinding.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||47 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||February 2020|
|Estimated Study Completion Date :||February 2020|
Experimental: autologous bone marrow mononuclear cells
a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
Biological: autologous bone marrow mononuclear cells
BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
Other Name: BMMNCs
Placebo Comparator: placebo infusion
a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
Other: Placebo Infusion
Placebo infusion of 0.9% Sodium Chloride
Other Name: Saline Infusion
- brain white matter and gray matter structural preservation on diffusion tensor magnetic resonance imaging (DTMRI) [ Time Frame: one year post infusion ]DTMRI quantitative indices of both macro and microscopic integrity will be evaluated and compared to DTMRI of immediate post-injury treated and non-treated controls.
- CNS white matter and gray matter preservation in regions of interest and improves functional and neurocognitive deficits in children after TBI [ Time Frame: one year post infusion ]
- Infusional toxicity safety evaluations [ Time Frame: 7 days post-infusion ]Murray Score and liver function tests
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01851083
|United States, Arizona|
|Phoenix Children's Hospital I University of Arizona|
|Phoenix, Arizona, United States, 85006|
|United States, Texas|
|The University of Texas Health Science Center at Houston|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Charles S Cox, Jr., M.D.||The University of Texas Health Science Center, Houston|